More
Bioinformatics Institute (BII)

BII was established in 2001 to train manpower and build capabilities in bioinformatics. BII focuses on theoretical approaches aimed at:
  • Understanding biomolecular mechanisms that underlie biological phenomena
  • Developing computational methods to support this discovery process
  • Experimental verification of predicted molecular and cellular functions of genes and proteins with biochemical methods
Research Capabilities
  • Biomolecular Function Discovery
  • Biomolecular Modelling and Design
  • Genome and Gene Expression Data Analysis
  • Imaging Infomatics
  • Translational Research (comprising of Natural Product Biology, Natural Product Chemistry and Antibody & Product Development Teams)
Visit BII


Bioprocessing Technology Institute (BTI)

BTI was established in 1990 with the mission to pursue innovative and cutting-edge research in bioprocess science and engineering leading to technologies which will impact biomedical science and bio-manufacturing as well as to nurture talent for the scientific community and industry. BTI specialises in:
  • Generating novel cell lines and biomolecules
  • Optimization of therapeutics production in prokaryotic and eukaryotic syste
  • Expansion and characterization of stem cells; product recovery, purification and analysis
  • Profiling of processes using “-omics” tools.
Research Capabilities
  • Immunology
  • Expression Engineering
  • Stem Cell Research
  • Animal Cell Technology
  • Microbial Cell
  • Downstream Processing
  • Analytics
  • "-OMICS" Technologies
Visit BTI


Experimental Therapeutics Centre (ETC)

ETC was set up in 2006 to play an increasingly important role in translating scientific discoveries into practical applications. From engaging in early stage drug discovery and development, to developing innovative research tools for clinical analysis, as well as setting up public-private partnerships to facilitate the advancement of drug candidates, ETC augments Singapore’s capabilities and resources in this spectrum of the drug discovery process. It is currently headed by CEO Dr Alex Matter.

Visit ETC


Genome Institute of Singapore (GIS)

Established in 2000 as the Singapore Genomics Program, GIS is a national flagship initiative with a global vision that seeks to use genomic sciences to improve public health and prosperity. As a centre for genomic discovery, GIS pursues the integration of technology, genetics, and biology towards the goal of individualised medicine. The scientific focus is to investigate diverse biological and biomedical problems, including cancer, infectious diseases, stem cells and development, with an emphasis on insights gleaned from genomic sequences and from technologies that probe gene regulation and its control.

Our seven research focus are:
  • Human Genetics
  • Infectious Diseases
  • Cancer Therapeutics and Stratified Oncology
  • Stem Cell and Developmental Biology
  • Cancer Stem Cell Biology
  • Computational and Systems Biology
  • Translational Research
Visit GIS 


Institute of Bioengineering and Nanotechnology (IBN)

Since 2003, IBN has carved out a unique niche at the interface of bioengineering and nanotechnology with its impactful research. Led by Executive Director, Professor Jackie Ying, the IBN conducts interdisciplinary research that brings together science, engineering and medicine.

Research Capabilities
  • Nanomedicine
  • Cell and Tissues Engineering
  • Biodevices and Diagnostics
  • Green Chemistry and Energy
Visit IBN


Institute of Medical Biology (IMB)

IMB was established in 2007 from the former Centre for Molecular Medicine. IMB’s Executive Director is Professor Birgit Lane. Its mission is to study mechanisms of human disease in order to discover new and effective therapeutic strategies for an improved quality of life. Our growing portfolio of strategic research topics aims to promote translational research on the mechanisms of human diseases with a cell-to-tissue emphasis that can help identify new therapeutic strategies for disease amelioration, cure, and eradication.

Research Capabilities
  • Stem Cells
  • Cancer
  • Genetic Diseases
  • Development and Differentiation
Visit IMB


Institute of Molecular and Cell Biology (IMCB)

The Institute of Molecular and Cell Biology (IMCB) was launched on 23 January 1985, with the official opening ceremony held on 2 October 1987 at the National University of Singapore (NUS). It subsequently became an autonomous research institute (RI) of A*STAR, moving to Biopolis in 2004. Today, IMCB has established itself as a world-class research institute in biomedical sciences with a focus on four major fields:
  • Animal Models of Development and Disease
  • Cancer Genetics and Therapeutics
  • Cell Biology in Health and Disease
  • Structural Biology and Drug Discovery
Research Capabilities
  • Advanced Molecular Pathology
  • Antibody Development
  • Cell Biology
  • Development Biology
  • Diagnostic and Therapeutic Development for Infectious Disease
  • Epigenetics
  • Genome-wide RNAi Screens
  • Humanized Model Organisms of Human Disease
  • Microfluidics Systems Biology
  • Quantitative Proteomics
  • Structural Biology
  • Translational Immunology
Visit IMCB


Singapore Bioimaging Consortium (SBIC)

SBIC was established in August 2004 to serve as a focal point for stimulating, funding, coordinating and reporting on the various bioimaging activities in Singapore. The SBIC plans to harness existing imaging expertise and capabilities in Singapore and develop them into a focused national platform to support the growth of multi-disciplinary research activities and speed the development and translation of biomedical research discoveries into clinical applications. In the SBIC, the four technology platforms used to support research in cancer, metabolic medicine and regenerative medicine are listed below.

Research Capabilities
  • Optical imaging
  • Image processing and management
  • Small animal imaging with Magnetic Resonance
  • Development of Chemical/Biological probes
Visit SBIC


Singapore Institute for Clinical Sciences (SICS)

The Singapore Institute for Clinical Sciences (SICS) was established in 2007 within the Agency for Science, Technology and Research (A*STAR). As A*STAR’s key initiative to develop world-class clinical sciences programs, we at SICS seek to better lives for the future through our firm scientific understanding of existing, emerging and potential healthcare challenges all across Asia’s dynamic landscape. We believe that scientific fundamentals are essential to anticipating tomorrow’s needs. SICS distinguishes itself through a focus on clinical sciences and the use of innovative approaches and technologies, enabling efficient and effective study of human health and diseases. Research by our clinical scientists span the full ‘bench to bedside’ spectrum of activities in metabolic diseases, (including obesity, diabetes and insulin resistance), pathways to normal growth and development (cognitive development, behavioural and clinical psychology among others), as well as nutritional sciences (functional food studies, satiety regulation, sensory and taste perception).

Broad research areas:
  • Nutrional Sciences & Human Physiology
  • Metabolic Disease
  • Developmental pathways to Health and Disease
Visit SICS


Singapore Immunology Network (SIgN)

The Singapore Immunology Network (SIgN) was initiated in December 2005 with the aim of expanding and strengthening immunology research capabilities in Singapore to support efficient translation into clinical applications in areas of medical needs. In January 2008, 6000m2 of new laboratory and office space was inaugurated as the home of SIgN, in the Immunos building at Biopolis. Human Immunology will be the focus of SIgN. Researchers at SIgN investigate immunity during infections and inflammatory conditions, including cancer, by using animal models to complement patient cohort studies, in an effort to translate bench discoveries into bedside medical treatments. Our Scientists' work is supported by cutting edge technological research platforms and core services. SIgN was also designed to attract and link up with companies in the biomedical field, feeding their pipelines with novel discoveries, in order to create a positive impact on Singapore’s economy. Since its establishment, SIgN has delivered outstanding scientific output that gained international recognition for Singapore’s Biomedical Sciences.

Research Capabilities
  • Infection
  • Inflammation
  • Immunoregulation
Visit SIgN